Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
U0267 Foam · 1 trial · 1 indication
Assessment (on a scale of 0 to 4) was made as a visual average of all lesions, except those on the face/scalp. 0=clear; minor residual discoloration; no erythema/scaling/plaque thickness (PT). 1=almost clear; occasional fine scale/faint erythema/barely perceptible PT. 2=mild; fine scales predominate; light red coloration/mild PT. 3=moderate; coarse scales predominate; moderate red coloration/moderate PT. 4=severe; thick tenacious scale predominates; deep red coloration/severe PT. Treatment success=ISGA score 0 or 1, and a minimum improvement in the ISGA score of 2 grades from BL to week 8.
| Arm | Type | Description |
|---|---|---|
| U0267 foam | EXPERIMENTAL | U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body. |
| Vehicle foam | PLACEBO_COMPARATOR | Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body. |
| Name | Type | Description |
|---|---|---|
| U0267 Foam | DRUG | All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp). |
| Vehicle foam | DRUG | All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp). |
Inclusion Criteria: * Male or female subjects at least 12 years old and in good general health. * Mild to moderate plaque-type psoriasis Exclusion Criteria: * Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulatio...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
U0267 Foam is an investigational small molecule therapy being developed for the treatment of psoriasis, specifically plaque-type psoriasis. It is formulated as a foam and is being studied in patients with this skin condition. GSK plc is developing the asset, which has reached Phase 3 clinical development.
U0267 Foam is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating the foam formulation in plaque-type psoriasis. The company holds the development rights for this dermatology asset.
U0267 Foam is in Phase 3 clinical development for plaque-type psoriasis. One Phase 3 trial has been completed, and no trials are currently listed as active. The asset remains investigational and has not been approved by the FDA for any indication.
U0267 Foam has been evaluated in the Phase 3 trial NCT00689481, titled a study to compare U0267 against vehicle in subjects with plaque-type psoriasis. The trial enrolled 323 participants in the United States, was randomized, double-blind, and placebo-controlled, and has completed.
U0267 Foam is not approved and remains an investigational therapy in Phase 3 clinical development for plaque-type psoriasis. Its only listed trial, NCT00689481, has completed, and no active trials are currently recorded for the asset.